CAI
Caris Life Sciences, Inc.
30.70$
+2.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.2% | +10.6% | +3.5% | +18.2% | +24.0% | -3.7% | -10.0% | -72.5% | -42.4% | -16.8% | +227.5% | |
| – | +10.6% | -0.5% | -6.2% | +3.8% | +56.8% | +126.9% | -57.0% | +140.4% | -53.0% | -11.1% | +362.5% | |
| – | +17.7% | -2.4% | -12.2% | -23.2% | +27.9% | +2.5% | +15.2% | +100.2% | -47.4% | +13.4% | +1,147.5% | |
| – | +22.5% | +2.4% | -10.3% | -0.9% | +85.2% | -61.7% | +185.3% | +209.1% | -70.3% | -45.6% | +1,109.5% | |
| – | +17.4% | +0.4% | +9.5% | +20.3% | +70.8% | -7.1% | -9.6% | -72.1% | +37.5% | +59.6% | +27.1% | |
| – | – | – | – | – | – | – | – | – | +4.3% | -19.2% | +60.8% | |
| – | – | – | +443.7% | +0.0% | +0.0% | +0.0% | – | – | +0.0% | +0.0% | +0.0% | |
| – | -59.7% | +348.0% | +692.4% | -20.3% | -25.8% | -28.1% | – | – | – | – | – | |
| – | +7.3% | +12.7% | +4.8% | +16.8% | +23.8% | -4.5% | -13.5% | +26.7% | +5.7% | +11.1% | -80.7% | |
| – | +58.8% | -12.6% | -24.7% | +58.5% | +63.7% | -32.5% | +11.4% | -57.3% | -30.5% | +73.9% | -23.1% | |
| – | +168.7% | -15.6% | -44.6% | +38.2% | +135.8% | -30.0% | -15.9% | -68.9% | -88.2% | +879.7% | -99.7% | |
| – | +5.1% | +42.2% | +15.4% | -43.3% | -5.9% | -1.1% | -49.7% | +643.8% | -2.2% | +4.2% | +41.1% | |
| – | – | – | – | – | – | – | – | – | -2.0% | +92.2% | +18.6% | |
| – | +6.7% | +4.1% | -0.6% | +23.2% | +24.3% | -1.1% | +1.3% | -342.4% | – | – | – | |
| – | +25.9% | +9.2% | +1.5% | +22.5% | +18.5% | +4.7% | +2.0% | -433.5% | – | – | – | |
| – | -6.7% | -0.8% | -7.6% | +1.1% | +1.1% | -9.1% | -0.3% | +1,319.5% | 0.0% | +0.0% | +13.8% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.